Justin Lindemann, MBChB MBA

AstraZeneca

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

3 more share only the name and are not shown

Trial papers in breast cancer

PubMed author-name match

Trials

Studies that name Justin Lindemann, MBChB MBA as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:11 UTC. Open this list on ClinicalTrials.gov

Ph1
NCT03616587 · Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
AstraZeneca · active not recruiting · ER+ HER2- Advanced Breast Cancer · study director
Ph1/Ph2
NCT01625286 · Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients
AstraZeneca · completed · Advanced or Metastatic Breast Cancer, ER+ve Advanced or Metastatic Breast Cancer · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

PubMed returned no clinical-trial papers for this author name in breast cancer.